PET/CT and MR Neuroimaging Methods to Study Alzheimer’s Disease

October 6th, 15:00 CEST

Key Learning Points

  • Neurodegenerative diseases
  • Alzheimer’s disease
  • Neuroimaging
  • Marmosets
  • PET/CT
  • MRI
  • Awake multimodal imaging
  • 18F-FDG
  • 11C-Pittsburgh Compound B (PiB)

What to expect?

This webinar will attract academic researchers, postgraduate students, principal investigators, and researchers in the pharmaceutical sector, particularly in drug development, working to fight neurodegenerative diseases. This webinar will benefit those working with small animals for drug discovery research seeking to understand better the role of cutting-edge imaging methods to complement their existing research programs.

Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice ( and I agree to the Terms of Use ( of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.


Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting nearly 55 million people worldwide and is expected to increase over the next several years. Our limited understanding of the mechanisms that trigger the emergence of AD has contributed to the lack of interventions that stop, prevent, or fully treat this disease.

We are working to establish the marmoset as the first primate-specific model to reveal the earliest cellular and molecular events of AD processes and allow charting of AD progression from its inception. We believe that the simultaneous assessment of genetic, molecular, functional, behavioral, and pathological phenotypes in marmosets will provide translatable knowledge of the origins and progression of AD in human populations. In this webinar, I will describe our use of multimodal neuroimaging techniques to evaluate AD-related phenotypes in our marmoset AD models, carrying all imaging in conscious, fully awake animals, thus avoiding the confounds of anesthesia.



Afonso Silva

Endowed Professor of Translational Neuroimaging & Neurobiology at the University of Pittsburgh

Afonso Silva is an Endowed Professor of Translational Neuroimaging & Neurobiology at the University of Pittsburgh. He is a neuroscientist with extensive training and experience in developing and applying multimodal neuroimaging methods to study the anatomical and functional organization of the brain. Dr. Silva is an expert in working with marmosets, a New World non-human primate with several advantages as an experimental model in neuroscience and neurological disorders.